BMS signs $674m GenAI drug discovery deal with VantAI

The partnership will focus on designing molecular glues for unspecified therapeutic targets.

Feb 14, 2024 - 18:00

BMS signs $674m GenAI drug discovery deal with VantAI

The partnership will focus on designing molecular glues for unspecified therapeutic targets.

Read the original article

Tags:

Previous Article

FDA cracks down on online retailers selling unapproved GLP-1 agonists

Grifols gears up for FDA approval of fibrinogen replacement therapy

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Eli Lilly achieving significant gains in obesity results

Eli Lilly achieving significant gains in obesity results

Jun 7, 2023

FDA fast track status granted to iECURE neonatal OTC deficiency treatment

FDA fast track status granted to iECURE neonatal OTC de...

May 9, 2024

Innate shelves lacutamab monotherapy plans in peripheral T cell lymphoma

Innate shelves lacutamab monotherapy plans in periphera...

Mar 24, 2024